<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471054</url>
  </required_header>
  <id_info>
    <org_study_id>Wills IRB# 11-089</org_study_id>
    <nct_id>NCT01471054</nct_id>
  </id_info>
  <brief_title>Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma</brief_title>
  <official_title>Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arman Mashayekhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex) and
      compare it with safety and efficacy of intravitreal bevacizumab in eyes with macular edema
      after plaque radiotherapy of uveal melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Plaque radiotherapy is a commonly used method for treatment of small and medium-sized uveal
      melanomas. Macular edema is one of the most common causes of visual loss after plaque
      radiotherapy and has been reported in up to 70% of patients with posterior uveal melanoma.
      Different methods have been proposed for treatment of post-radiation macular edema and
      include periocular steroid, intravitreal steroid, intravitreal vascular endothelial growth
      factor (VEGF) inhibitors, photodynamic therapy, and macular laser photocoagulation.

      Injection of intravitreal triamcinolone (a form of steroid) has been found to be useful for
      treatment of different forms of macular edema but is associated with considerable rates of
      increased intraocular pressure (glaucoma). Dexamethasone is more potent than triamcinolone
      and can be safely injected directly into the vitreous cavity (intravitreal injection) but
      unfortunately its use in the form of intravitreal injection is not practical due to the short
      half-life of intraocular dexamethasone (about 3 hours).

      Within the past several years, tiny drug delivery systems have been developed that allow
      sustained release of minute amounts of steroid into the back part (vitreous cavity) of the
      eye, when they are implanted into the vitreous cavity. Ozurdex is a biodegradable
      dexamethasone intravitreal implant that has been shown to be well-tolerated and effective for
      up to 6 months in reducing vision loss and improving visual outcome in eyes with different
      types of macular edema including those secondary to diabetic retinopathy and retinal vein
      occlusion.

      In this study the investigators would like to evaluate the safety and effectiveness of
      Ozurdex (dexamethasone intravitreal implant) for treatment of macular edema developing after
      plaque radiotherapy of uveal melanoma.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Could not enroll enough patients.
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eyes showing &gt;=2 lines of improvement in best-corrected visual acuity</measure>
    <time_frame>At 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in central subfield retinal thickness</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of glaucoma</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of cataract</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of retinal detachment</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of vitreous hemorrhage</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Macular Edema</condition>
  <condition>Cystoid Macular Edema</condition>
  <condition>Uveal Melanoma</condition>
  <condition>Radiation Maculopathy</condition>
  <condition>Radiation Retinopathy</condition>
  <arm_group>
    <arm_group_label>Ozurdex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be followed at 1 week after Ozurdex insertion (0.7 mg) and then at 1,2, 3,4, 5, and 6 months. Following the 6-month visit, patients will be seen every 2 months. At each visit patients will be checked for side effects of treatment, measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Each eye in the Ozurdex group can have a maximum total of three Ozurdex insertions at minimum of 4-month intervals in the first year after enrolling into the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be followed at 1 week after the initial bevacizumab injection and then at 1,2, 3,4, 5, and 6 months after implant. Following the 6-month visit, the patients will be examined every 4-8 weeks depending on the status of their macular edema. At each visit patients will be checked for side effects of treatment, measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Eyes in the Bevacizumab group can have a maximum total of twelve (12) bevacizumab injections at minimum of 4-week intervals in the first year after enrolling into the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <description>Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:
i.The study eye must have shown initial favorable response to prior Ozurdex implant (&gt;10% decrease in central macular thickness with maintenance [change in BCVA of &lt;=1 line] or improvement of visual acuity [increase of BCVA of &gt;1 line]) ii. Interval since last Ozurdex implant should be &gt; 4 and &lt; 12 months. iii. The study eye must show definite evidence of recurrence of macular edema.</description>
    <arm_group_label>Ozurdex</arm_group_label>
    <other_name>Dexamethasone intravitreal implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria:

               1. Patient age 18 years or more.

               2. Uveal melanoma treated with I-125 plaque radiotherapy.

               3. Visual acuity between 20/40 to 20/400 secondary to post-radiation macular edema.

               4. Central subfield retinal thickness &gt; 300 micron.

               5. Duration of macular edema &lt; 12 months.

               6. No potential contributing causes of decreased vision other than macular edema.

          -  Exclusion criteria:

               1. Visual acuity worse than 20/400 or better than 20/40.

               2. Monocular patient or poor vision in the non-study eye (&lt;20/80).

               3. History of vitrectomy surgery.

               4. Panretinal photocoagulation or intraocular surgery within 3 months of enrollment.

               5. Concomitant or previous radiation optic neuropathy.

               6. Use of periocular, intravitreal, or systemic steroids within 6 month of
                  enrollment in the study eye.

               7. Use of intravitreal VEGF antagonist within 6 weeks of enrollment.

               8. History of ocular hypertension or glaucoma, or IOP&gt;21 mmHg.

               9. History of steroid-induced glaucoma in either eye.

              10. Active ocular infection or history of herpetic eye infection.

              11. Clinically significant epiretinal membrane in the study eye.

              12. Iris neovascularization in the study eye.

              13. Clinically significant media opacity preventing acquisition of good-quality OCT
                  in the study eye.

              14. Aphakia or anterior chamber intraocular lens.

              15. Poorly controlled diabetes (Hemoglobin A1c level &gt;13%).

              16. Poorly controlled hypertension (Systolic pressure &gt; 160 mm Hg or diastolic
                  pressure &gt; 90 mm Hg).

              17. Pregnancy (women of childbearing age should have negative pregnancy test and use
                  contraception).

              18. Presence of any ocular condition that in the opinion of one of the investigators
                  will prevent at least 2 lines of improvement in best-corrected visual acuity.

              19. Interval between plaque radiotherapy for uveal melanoma and intended date of
                  dexamethasone intravitreal implant of less than 6 months.

              20. Evidence of activity or inadequate regression of the treated uveal melanoma after
                  plaque radiotherapy (based on the judgment of the study investigators).

              21. Known allergy or hypersensitivity to any of the study medications or their
                  components.

              22. History of prior myocardial infarction or stroke.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armen Mashayekhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Hospital IRB Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ocular Oncology Service, Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, Brady LW. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol. 2002 Jul;120(7):933-40.</citation>
    <PMID>12096964</PMID>
  </reference>
  <reference>
    <citation>Horgan N, Shields CL, Mashayekhi A, Teixeira LF, Materin MA, Shields JA. Early macular morphological changes following plaque radiotherapy for uveal melanoma. Retina. 2008 Feb;28(2):263-73. doi: 10.1097/IAE.0b013e31814b1b75.</citation>
    <PMID>18301032</PMID>
  </reference>
  <reference>
    <citation>Horgan N, Shields CL, Mashayekhi A, Salazar PF, Materin MA, O'Regan M, Shields JA. Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial. Ophthalmology. 2009 Jul;116(7):1383-90. doi: 10.1016/j.ophtha.2009.01.051. Epub 2009 May 30.</citation>
    <PMID>19481812</PMID>
  </reference>
  <reference>
    <citation>Sutter FK, Gillies MC. Intravitreal triamcinolone for radiation-induced macular edema. Arch Ophthalmol. 2003 Oct;121(10):1491-3.</citation>
    <PMID>14557194</PMID>
  </reference>
  <reference>
    <citation>Gupta A, Muecke JS. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina. 2008 Jul-Aug;28(7):964-8. doi: 10.1097/IAE.0b013e3181706302.</citation>
    <PMID>18698298</PMID>
  </reference>
  <reference>
    <citation>Bakri SJ, Beer PM. Photodynamic therapy for maculopathy due to radiation retinopathy. Eye (Lond). 2005 Jul;19(7):795-9.</citation>
    <PMID>15359269</PMID>
  </reference>
  <reference>
    <citation>Hykin PG, Shields CL, Shields JA, Arevalo JF. The efficacy of focal laser therapy in radiation-induced macular edema. Ophthalmology. 1998 Aug;105(8):1425-9.</citation>
    <PMID>9709753</PMID>
  </reference>
  <reference>
    <citation>Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol. 2003 Feb;135(2):246-9.</citation>
    <PMID>12566041</PMID>
  </reference>
  <reference>
    <citation>Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002 May;109(5):920-7.</citation>
    <PMID>11986098</PMID>
  </reference>
  <reference>
    <citation>Scott IU, Flynn HW Jr, Rosenfeld PJ. Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am J Ophthalmol. 2003 Oct;136(4):737-9.</citation>
    <PMID>14516818</PMID>
  </reference>
  <reference>
    <citation>Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009 Jun;147(6):1048-54, 1054.e1-2. doi: 10.1016/j.ajo.2008.12.033. Epub 2009 Mar 9.</citation>
    <PMID>19268890</PMID>
  </reference>
  <reference>
    <citation>Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007 Mar;125(3):309-17.</citation>
    <PMID>17353400</PMID>
  </reference>
  <reference>
    <citation>Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010 Mar;128(3):289-96. doi: 10.1001/archophthalmol.2010.21.</citation>
    <PMID>20212197</PMID>
  </reference>
  <reference>
    <citation>Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May;129(5):545-53. doi: 10.1001/archophthalmol.2010.339. Epub 2011 Jan 10.</citation>
    <PMID>21220619</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>December 9, 2016</last_update_submitted>
  <last_update_submitted_qc>December 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Arman Mashayekhi</investigator_full_name>
    <investigator_title>Principal Investigator, Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Plaque radiotherapy</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>Macular edema</keyword>
  <keyword>Cystoid macular edema</keyword>
  <keyword>Uveal melanoma</keyword>
  <keyword>Radiation maculopathy</keyword>
  <keyword>Radiation retinopathy</keyword>
  <keyword>Ozurdex</keyword>
  <keyword>Dexamethasone intravitreal implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 3, 2017</submitted>
    <returned>December 4, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

